Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Net Letter
2016:82:1;112-112
doi: 10.4103/0378-6323.157457
PMID: 26728835

Erythrodermic pityriasis rubra pilaris: Dramatic response to infliximab therapy

Ayse Serap Karadag1 , Mukaddes Kavala1 , Emin Ozlu1 , Seyma Ozkanlı2 , İlkin Zindancı1 , Zafer Turkoglu1
1 Department of Dermatology, Istanbul Medeniyet University, Goztepe Research and Training Hospital, Istanbul, Turkey
2 Department of Pathology, Istanbul Medeniyet University, Goztepe Research and Training Hospital, Istanbul, Turkey

Correspondence Address:
Ayse Serap Karadag
Istanbul Medeniyet University, Goztepe Research and Training Hospital, Dermatology Istanbul
Turkey
How to cite this article:
Karadag AS, Kavala M, Ozlu E, Ozkanlı S, Zindancı &, Turkoglu Z. Erythrodermic pityriasis rubra pilaris: Dramatic response to infliximab therapy. Indian J Dermatol Venereol Leprol 2016;82:112
Copyright: (C)2016 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Pityriasis rubra pilaris is a chronic papulo-squamous skin disorder characterized by skin and nail involvement.[1] The exact etiology is unknown. Vitamin A deficiency, infections, trauma and impaired immune responses are among the suggested causes.[2] A variety of topical and systemic treatment options are available.[3] This case is reported due to a dramatic response obtained with infliximab therapy, when various other systemic medications failed to produce a therapeutic response.

A 31-year-old woman presented to our clinic with a 4-year history of erythematous plaques over the upper half of her body which was spreading to the extremities. Dermatological examination revealed pink to red follicular papules which coalesced to form plaques. These were located over the face, neck, trunk, upper and lower extremities with patches of normal skin in between [Figure - 1]. There was no history of similar complaints in her family. Laboratory tests including complete hemogram, urinalysis, liver and kidney function tests, C-reactive protein, anti-HCV, anti-HIV, anti-HBsAg, and Mantoux test were within normal limits. Histopathological examination of the skin biopsy revealed hyperkeratosis, irregular acanthosis, broad rete ridges and thick suprapapillary plates. There was a superficial perivascular lymphocytic infiltrate in the dermis [Figure - 2].

Figure 1: Erythematous follicular papules and plaques over the lower limb, with islands of normal skin
Figure 2: Hyperkeratosis, irregular acanthosis, and thick suprapapillary plates (H and E, x100)

Based on the clinical and histopathological findings, the patient was diagnosed with pityriasis rubra pilaris. The patient had previously received systemic retinoids, phototherapy (nbUVB, PUVA), retinoic acid and nbUVB (re-nbUVB) combination, with no improvement. She developed erythroderma since the last 4 months [Figure - 3]. We treated her with methotrexate 15 mg/week for 3 months but the patient's lesions did not improve. Infliximab therapy was planned after ruling out contraindications. Two doses of 5 mg/kg of intravenous infliximab was administered at a two week interval, which resulted in a near total disease regression [Figure - 4]. The patient continued to receive this therapy similar to our psoriasis protocol (week 0, 2, 6, and then once in 2 months for a total duration of 1 year). She did not have any relapse after stopping medications during her two years of follow up.

Figure 3: Erythroderma
Figure 4: Total resolution after treatment

The treatment of pityriasis rubra pilaris is based upon anecdotal reports due to its rarity, lack of controlled studies and idiopathic nature of the disorder. Many therapies have been used to treat this condition and include high-dose vitamin A, systemic retinoids, methotrexate, azathioprine, cyclosporine, stanozolol, phototherapy and extracorporeal phototherapy. Systemic retinoids and methotrexate are most commonly used. Considering the overlapping characteristics of pityriasis rubra pilaris and psoriasis in terms of clinical appearance and response to therapy, previous studies have reported that biologicals with proven efficacy in psoriasis can also be used for the treatment of pityriasis rubra pilaris.[3]

TNF-alpha is a pro-inflammatory cytokine that acts as an immunomodulator in various systemic and dermatological disorders. Infliximab is a chimeric monoclonal antibody that binds to TNF-alpha. The drug was initially developed for the treatment of Crohn's disease. Subsequent reports indicated efficacy in the treatment of inflammatory dermatoses including psoriasis, hidradenitis suppurativa and pyoderma gangrenosum.[4] In 2013, a systematic review on the use of TNF-alpha antagonists in patients with type 1 pityriasis rubra pilaris was published.[5] A total of 15 patients received therapy with TNF-alpha antagonists, and there was complete response in 12 (80%) patients, partial response in two, and no response in one patient. TNF-alpha antagonists such as infliximab, etanercept or adalimumab were used in the treatment of patients as monotherapy, or in combination with other drugs such as methotrexate and acitretin. Infliximab was the most commonly used TNF-alpha antagonist. A dose of 5 mg/kg was administered at weeks 0, 2, 6, and then every 8 weeks in accordance with the treatment protocol for psoriasis. None of the patients developed any side effects. Considering the rapid and excellent response to infliximab, the researchers suggested that TNF-alpha plays a very important role in the pathophysiology of pityriasis rubra pilaris.[5]

Infliximab can be used as an alternative in the treatment of patients with adult onset treatment resistant pityriasis rubra pilaris. However, larger studies are necessary to establish the efficacy of the drug.

References
1.
Misery I, Faure M, Claidy A. Pityriasis rubra pilaris and human immunodeficiency virus infection – type 6 pityriasis rubra pilaris?. Br J Dermatol 1996;135:1008-9.
[Google Scholar]
2.
Behr FD, Bangert JL, Hansen RC. Atypical pityriasis rubra pilaris associated with arthropathy and osteoporosis: A case report with 15-year follow-up. Pediatr Dermatol 2002;19:46-51.
[Google Scholar]
3.
Liao WC, Mutasim DF. Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol 2005;141:423-5.
[Google Scholar]
4.
Ruiz-Genao DP, Lopez-Estebaranz JL, Naz-Villalba E, Gamo-Villegas R, Calzado-Villarreal L, Pinedo-Moraleda F. Pityriasis rubra pilaris successfully treated with infliximab. Acta Derm Venereol 2007;87:552-3.
[Google Scholar]
5.
Petrof G, Almaani N, Archer CB, Griffiths WA, Smith CH. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. J Eur Acad Dermatol Venereol 2013;27:131-5.
[Google Scholar]

Fulltext Views
256

PDF downloads
82
Show Sections